Oscar Fernandez-Capetillo Group

The Fernández-Capetillo laboratory focuses on the use of cell-based phenotypic screens for the development of new medicines. Neglected until rather recently, due to a focus on target-oriented drug development, phenotypic screens have yielded some of the most important medical advances to our societies. With the help of automatized microscopes, the laboratory designs phenotypic screens that aim to mimic a disease condition. The research mostly focuses on diseases that are largely neglected by the industry, or in the repositioning of current medically approved drugs for their use in other diseases.

Professor

Oscar Fernandez-Capetillo

Organizational unit: Oscar Fernandez-Capetillo's Group
E-mail: oscar.fernandez-capetillo@ki.se

Research interests

Our recently started laboratory at Karolinska Institutet focuses on the implementation of cell-based phenotypic screens oriented to the discovery and development of novel molecules to improve the efficiency of various diseases. At present, our interests are spread among a variety of topics, such as the discovery of new medicines for amyotrophic lateral sclerosis (ALS), the search for chemical modulators of the immune response, or the discovery of molecules that can regulate the levels of RNA and protein production in cells.

Group Members

Mirela BalanPostdoc
Jordi Carreras PuigvertAssistant professor, Project manager
Alba CormanPhD student
Oscar Fernandez-CapetilloProfessor
Maria HäggbladResearch engineer
Daniela HühnPostdoc
Louise LidemalmLaboratory technician
Per MobergResearch coordinator
Kirsten TschapaldaPostdoc
Melania ZauriAssociated

The lab is looking for talented and highly motivated posdoctoral fellows. We seek candidates that have a strong expertise in molecular and cell biology. The person should have deep knowledge in cancer biology or ALS research. Preference will be given to applicants with skills in high-content imaging, automated image processing and gene knockout (CRISPR/Cas9) strategies. The successful candidate should have a strong publication record. Complete fluency in both written and spoken English is a request. The candidate´s personal skills will be highly valued.

Please contact Per Moberg at per.moberg@ki.se directly if you are interested. Postdocs are asked to send a motivation letter and their CV.

Alumni

Kirsten Tschapalda now Senior Scientist at AstraZeneca, UK
Bomi Jung now Senior Scientist at AstraZeneca, Mölndal, Sweden

Key Publications

A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors.
Ruiz S, Mayor-Ruiz C, Lafarga V, Murga M, Vega-Sendino M, Ortega S, et al
Mol. Cell 2016 04;62(2):307-13

USP7 is a SUMO deubiquitinase essential for DNA replication.
Lecona E, Rodriguez-Acebes S, Specks J, Lopez-Contreras A, Ruppen I, Murga M, et al
Nat. Struct. Mol. Biol. 2016 Apr;23(4):270-7

NSMCE2 suppresses cancer and aging in mice independently of its SUMO ligase activity.
Jacome A, Gutierrez-Martinez P, Schiavoni F, Tenaglia E, Martinez P, Rodríguez-Acebes S, et al
EMBO J. 2015 Nov;34(21):2604-19

Limiting replication stress during somatic cell reprogramming reduces genomic instability in induced pluripotent stem cells.
Ruiz S, Lopez-Contreras A, Gabut M, Marion R, Gutierrez-Martinez P, Bua S, et al
Nat Commun 2015 Aug;6():8036

Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice.
Lopez-Contreras A, Specks J, Barlow J, Ambrogio C, Desler C, Vikingsson S, et al
Genes Dev. 2015 Apr;29(7):690-5

The maternal side of Fanconi Anemia.
Ruiz S, Fernandez-Capetillo O
Mol. Cell 2014 Sep;55(6):803-804

External funding

Vetenskapsrådet

Cancerfonden